• HIDEN lncRNA Stabilizes FZD5 During Endoderm Differentiation

  2026-09-30

  Lu et al. identify HIDEN as a functional gene-desert lncRNA that promotes human definitive endoderm differentiation by facilitating IMP1 binding to FZD5 mRNA. Their perturbation, interaction, RNA-stability, and rescue experiments connect a distal noncoding transcript to WNT signaling and provide a framework for studying poorly annotated lncRNAs.

• H5N1 mRNA Vaccine Protection in Lactating Dairy Cows

  2026-09-30

  A hemagglutinin-encoding mRNA–lipid nanoparticle vaccine protected lactating dairy cows from high-dose H5N1 challenge without apparent effects on health or milk production. The study is important because it tests mRNA vaccine performance in a production-relevant, high-risk host and reports durable protection even when serum antibody levels had declined substantially.

• Lipid Peroxidation (MDA) Assay Kit: From Signal to Mechanism

  2026-09-29

  Discover how the Lipid Peroxidation (MDA) Assay Kit converts malondialdehyde detection into a rigorous strategy for studying ferroptosis and oxidative injury. This guide connects assay chemistry, preanalytical controls, and orthogonal validation using the doxorubicin–Beclin1 liver injury model.

• Astrocytic GAT-3 and Dentate Gyrus Memory

  2026-09-29

  The reference study identifies astrocytic GAT-3 as an active regulator of dentate gyrus synaptic transmission rather than merely a GABA-clearance mechanism. By linking GAT-3-dependent astrocytic calcium signaling to reverse Na+/Ca2+ exchange, presynaptic GluN2B-containing NMDARs, and contextual fear memory, it provides a mechanistic framework for studying glia–neuron control of hippocampal function.

• PXR Activation, Liver Regeneration, and CYP Activity

  2026-09-28

  Bi et al. show that activating pregnane X receptor with pregnenolone-16α-carbonitrile in rats links liver enlargement and regeneration with increased CYP3A1/2 and CYP2C6/11 activity. The work is important because it evaluates both hepatic structure and functional drug metabolism, including after two-thirds partial hepatectomy.

• PID1 and Cholesterol Metabolism in Tumor Macrophages

  2026-09-28

  This paper examines how PID1 relates to cholesterol handling and macrophage state in tumors. Its reported findings connect myeloid PID1 deficiency with altered LDL uptake, cholesterol oxidation products and macrophage signaling, using human tumor data and preclinical models.

• CTP for Translational mRNA: From IVT to p21 Therapy

  2026-09-27

  How CTP supports in vitro mRNA synthesis—and what a bladder cancer p21 mRNA-LNP study teaches translational teams about connecting reagent quality, experimental control, and localized delivery.

• CGP 55845 Hydrochloride for Reliable Assays

  2026-09-26

  Learn how CGP 55845 hydrochloride (SKU B5086) can help researchers isolate GABAB receptor-dependent effects in neurotransmission and cell-based experiments. This scenario-driven guide covers assay design, concentration interpretation, solution handling, and the limits of applying a receptor antagonist to viability readouts.

• Prestained Protein Marker: F4005 Workflow Guide

  2026-09-25

  Practical guidance for interpreting protein blots alongside cell viability, proliferation, and cytotoxicity assays. Learn how APExBIO SKU F4005 supports size verification and workflow compatibility without confusing a protein marker with a direct measure of cell viability.

• Angiotensin I/II (1-5): RAS Workflow Guide

  2026-09-25

  Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for experiments examining renin-angiotensin system activity and related cardiovascular or renal endpoints. Use it in an established RAS workflow with appropriate vehicle controls; it is not a general-purpose peptide for unrelated signaling studies, and the product dossier does not specify assay concentrations or potency.

• AmpliFold Capture-and-Release Boosts LFA Sensitivity

  2026-09-24

  The AmpliFold strategy uses a cleavable capture step followed by release and high-affinity rebinding to address kinetic limits in lateral flow assays. In a HER2 model, it improved sensitivity by up to 16-fold in selected configurations, including detection with large nanoparticles in buffer and human serum.

• Capecitabine Assays: Activation or Resistance?

  2026-09-24

  Capecitabine response in a tumor model can reflect both cellular sensitivity and the model’s capacity to activate this prodrug. This article connects capecitabine pharmacology with patient-derived gastric cancer assembloid findings to help researchers distinguish those effects when designing preclinical assays.

• CCT007093: A PPM1D Inhibitor for P38 Studies

  2026-09-23

  Use CCT007093 to test how PPM1D/WIP1 restrains P38 signaling, from renal tubular pyroptosis models to cancer-cell assays. Its value is strongest in a controlled workflow that pairs pathway readouts with viability, genetic, and inhibitor-rescue controls.

• FDA Library Screening Finds Four MERS-CoV Inhibitors

  2026-09-23

  De Wilde and colleagues screened an FDA-approved compound library and identified chloroquine, chlorpromazine, loperamide, and lopinavir as low-micromolar inhibitors of MERS-CoV replication in cell culture. The study established a practical repurposing framework, while also showing why cellular activity must be followed by exposure, mechanism, animal, and clinical validation.

• Interpreting In Vitro Cancer Drug Responses

  2026-09-22

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent drug-response phenotypes. This framework improves assay design, time-course interpretation, and evaluation of anti-cancer compounds in cancer research.

656 records 1/44 page Next 12345 下5页 Last page